echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first domestically produced PD-(L)1 monoclonal antibody head-to-head Phase 3 clinical trial!

    The first domestically produced PD-(L)1 monoclonal antibody head-to-head Phase 3 clinical trial!

    • Last Update: 2021-12-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Chia Tai Tianqing Pharmaceutical Group announced the launch of an "evaluation of TQB2450 injection combined with platinum-containing chemotherapy followed by sequential TQB2450 injection combined with anlotinib hydrochloride capsules versus tislelizumab injection combined with platinum-containing chemotherapy as the first-line treatment A randomized, open-label, parallel-controlled, multi-center phase III clinical trial on the effectiveness and safety of advanced non-squamous non-small cell lung cancer"


    Prior to this, Chia Tai Tianqing has launched the first-line phase 3 of lung cancer compared with K drug: TQB2450 injection combined with Anlotinib hydrochloride capsules compared with pembrolizumab injection in the first-line treatment of advanced non-small cell lung cancer.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.